Randomized placebo‐controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly
British Journal of Clinical Pharmacology – December 2023

van Kraaij SJW, Borghans L, Klaassen ES, Gal P, van der Grond J, Tripp K, Winrow C, Glasser C, Groeneveld GJ. Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly. Br J Clin Pharmacol. 2023 Dec;89(12):3606-3617. doi: 10.1111/bcp.15861. Epub 2023 Aug 13. PMID: 37488930.
View publication

First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator
Clinical and Translational Science – August 2023

van Kraaij SJW, Gal P, Borghans LGJM, Klaassen ES, Dijkstra F, Winrow C, Glasser C, Groeneveld GJ. First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395. doi: 10.1111/cts.13537. Epub 2023 May 3. PMID: 37118895; PMCID: PMC10432884.
View publication

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Journal of Neuroinflammation – September 2021

Correia SS, Liu G, Jacobson S, Bernier SG, Tobin JV, Schwartzkopf CD, Atwater E, Lonie E, Rivers S, Carvalho A, Germano P, Tang K, Iyengar RR, Currie MG, Hadcock JR, Winrow CJ, Jones JE. The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system. J Neuroinflammation. 2021 Sep 18;18(1):213. doi: 10.1186/s12974-021-02275-z. PMID: 34537066; PMCID: PMC8449877.
View publication

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
Frontiers in Pharmacology – May 2021

Correia SS, Iyengar RR, Germano P, Tang K, Bernier SG, Schwartzkopf CD, Tobin J, Lee TW, Liu G, Jacobson S, Carvalho A, Rennie GR, Jung J, Renhowe PA, Lonie E, Winrow CJ, Hadcock JR, Jones JE, Currie MG. The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561. doi: 10.3389/fphar.2021.656561. PMID: 34108877; PMCID: PMC8181742.
View publication

Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential
Nitric Oxide – August 2018

Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide. 2018 Aug 1;78:72-80. doi: 10.1016/j.niox.2018.05.009. Epub 2018 May 31. PMID: 29859918.
View publication

PROMIS® for MELAS: Measuring What’s Important from the Patient and Clinician Perspectives
UMDF Mito Med 2024 – June 2024

Medrano P, Banderas B, Walker M, Settel L, Berger S, Shields A, Webster M, Chickering J, Glasser C, Gwaltney C, Wilson P

View the poster here.

Results from a Phase 2a study evaluating zagociguat, a CNS-penetrant sGC stimulator, in adults with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
UMDF Mito Med 2023 – June 2023

Chad Glasser, Amel Karaa, Marni J. Falk, Amy Goldstein, Michio Hirano, Phebe Wilson, Jennifer Chickering, Sara Nguyen, Jennifer King, Meghan Savard, Chris Winrow, Bruce Kinon

View the poster here.

MitoAction 2024 Town Meeting
January 2024

Jennifer Chickering, Vice President of Program Leadership
View presentation

Tisento Therapeutics Clinical Trial Update
UMDF Bench to Bedside – December 2023

Chad Glasser, Senior Director of Clinical Research
View presentation

Clinical Data Update from Phase 2a Study of CY6463 in MELAS
Hosted by UMDF – June 2022

View presentation